Abstracts tagged "Late-Breaking 2016"

Abstract Number: 13L • 2016 ACR/ARHP Annual Meeting
Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial
Jens Humrich¹, Caroline von Spee-Mayer², Elise Siegert³, Angelika Rose², Martina Bertolo⁴, Philipp Enghard⁵, Falk Hiepe⁶, Tobias Alexander⁷, Eugen Feist⁸, Andreas Radbruch⁹, Gerd R. Burmester¹⁰ and Gabriela Riemekasten¹¹, ¹Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ²Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ³Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ⁴Department of Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, ⁵Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, ⁶Charité – Universitätsmedizin, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁸Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁹Deutsches Rheumaforschungszentrum, Berlin, Germany, ¹⁰Charité – University Medicine Berlin, Berlin, Germany, ¹¹Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany

Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 14L • 2016 ACR/ARHP Annual Meeting
Use of Intravenous Epoprostenol As a Treatment for the Digital Vasculopathy Associated with the Scleroderma Spectrum of Diseases
Shing Law¹, Robert W. Simms² and Harrison W. Farber³, ¹Rheumatology, Boston Medical Center, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Pulmonary Center, Boston University Medical Center, Boston, MA

Background/Purpose: Intravenous prostanoid therapy is recommended for severe systemic sclerosis related digital vasculopathy. Evidence to support this recommendation is limited. Our objective is to evaluate…
Abstract Number: 15L • 2016 ACR/ARHP Annual Meeting
Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis vulgaris and Normalizes Skin Pathology Via Concurrent Regulation of IL-17 and IL-10 Levels
Alexandra Zanin-Zhorov¹, Jonathan Weiss¹, Alissa Trzeciak¹, Carmen Arencibia¹, Seetharam Polimera¹, Wei Chen¹, Jingya Zhang¹, Melanie Nyuydzefe¹, Judilyn Fuentes-Duculan², Kathleen Bonifacio², Norma Kunjravia², Inna Cueto², Mark Berger¹, James Krueger², Samuel Waksal¹ and John Ryan¹, ¹Kadmon, New York, NY, ²Rockefeller University, New York, NY

Background/Purpose: Rho-associated kinase 2 (ROCK2) was shown to be implicated in regulation of autoimmunity in mice and humans1. Previous findings demonstrated that oral administration of…
Abstract Number: 16L • 2016 ACR/ARHP Annual Meeting
Comparison of Systematic Vs Individually Tailored Rituximab Regimen to Maintain ANCA-Associated–Vasculitis Remission: Results of a Prospective, Randomized–Controlled, Phase 3 Trial
Pierre Charles¹, Benjamin Terrier², Pascal Cohen³, Stanislas Faguer⁴, Antoine Huart⁵, Mohamed Hamidou⁶, Christian Agard⁷, Bernard Bonnotte⁸, Maxime Samson⁸, Alexandre Karras⁹, Noémie Jourde-Chiche¹⁰, François Lifermann¹¹, Pierre Gobert¹², Catherine Hanrotel-Saliou¹³, Pascal Godmer¹⁴, Nicolas Martin Silva¹⁵, Grégory Pugnet¹⁶, Marie Matignon¹⁷, Olivier Aumaître¹⁸, Estibaliz Lazaro¹⁹, Luc Mouthon²⁰, Loïc Guillevin²¹ and French Vasculitis Study Group, ¹Service de Médecine Interne, Hôpital Cochin, Paris, France, ²Internal Medicine, Cochin University Hospital, Paris, France, ³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁴2Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France, ⁵CHU, Toulouse, France, ⁶Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁸Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁹Nephrology, HEGP, Paris, France, ¹⁰Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ¹¹CH Dax, Dax, France, ¹²Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹³CHU Cavale Blanche, Brest, Brest, France, ¹⁴CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Caen University Hospital, Caen, France, ¹⁶Service de Médecine Interne, CHU de Toulouse, Toulouse, Toulouse, France, ¹⁷Service de Néphrologie, Hôpital Henri-Mondor, Créteil, Créteil, France, ¹⁸CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ¹⁹Service de Médecine Interne et Maladies Infectieuses, CHU de Bordeaux, Pessac, France, ²⁰Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France

Background/Purpose: Remission of ANCA-associated vasculitides (AAVs) can be induced with combined glucocorticoids and cyclophosphamide or rituximab (RTX) with comparable efficacy.1 RTX superiority to azathioprine was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].